Surgery Today

, Volume 48, Issue 5, pp 517–524 | Cite as

The preoperative HbA1c level is an independent prognostic factor for the postoperative survival after resection of non-small cell lung cancer in elderly patients

  • Makoto Motoishi
  • Satoru Sawai
  • Tetsuo Hori
  • Naoki Yamashita
Original Article



The aim of this study was to investigate the influence of a history of diabetes mellitus (DM) and the glycated hemoglobin (HbA1c) level on the survival in patients who underwent complete resection for non-small cell lung cancer (NSCLC).


Of the patients who underwent complete resection for NSCLC between 2007 and 2015, 468 were classified into DM (who were currently taking medication for DM) and no DM groups as well as into high HbA1c (≥ 6.5) and normal HbA1c (< 6.5) groups.


The overall survival (OS) did not differ significantly between either pair of groups. Among the elderly patients, the OS did not differ significantly between the DM and no DM groups, but was significantly higher in the normal-HbA1c group than in the high-HbA1c group (5-year survival rate: 84.7 versus 37.2%, respectively, p < 0.01). In the elderly patients, non-adenocarcinoma histology, advanced stage, a high Charlson comorbidity index, and a high preoperative HbA1c level were found to be independent risk factors for the OS.


We revealed that a high preoperative HbA1c level was associated with a poor OS in elderly patients who underwent complete resection for NSCLC. This suggests that it is necessary to achieve diabetic control prior to complete resection in NSCLC patients.


Diabetes mellitus (DM) Glycated hemoglobin (HbA1c) Non-small cell lung cancer (NSCLC) Operation 


Compliance with ethical standards

Conflict of interest

The authors declare no conflicts of interests associated with this study.


  1. 1.
    Katanoda K, Hori M, Matsuda T, Shibata A, Nishino Y, Hattori M et al. An updated report on the trends in cancer incidence and mortality in Japan, 1958–2013. Jpn J Clin Oncol. 2015;45:390–401.CrossRefPubMedGoogle Scholar
  2. 2.
    Danaei G, Finucane MM, Lu Y, Singh GM, Cowan MJ, Paciorek CJ et al. National, regional, and global trends in fasting plasma glucose and diabetes prevalence since 1980: systematic analysis of health examination surveys and epidemiological studies with 370 country-years and 2·7 million participants. Lancet. 2011;378:31–40.CrossRefPubMedGoogle Scholar
  3. 3.
    Yuhara H, Steinmaus C, Cohen SE, Corley DA, Tei Y, Buffler PA. Is diabetes mellitus an independent risk factor for colon cancer and rectal cancer? Am J Gastroenterol. 2011;106:1911–21.CrossRefPubMedPubMedCentralGoogle Scholar
  4. 4.
    Liaw YP, Ko PC, Jan SR, Huang JY, Nfor ON, Lung CC, et al. Implications of type 1/2 diabetes mellitus in breast cancer development: a general female Population-based cohort study. J Cancer. 2015;6:734–9.CrossRefPubMedPubMedCentralGoogle Scholar
  5. 5.
    Lo SF, Chang SN, Muo CH, Chen SY, Liao FY, Dee SW, et al. Modest increase in risk of specific types of cancer types in type 2 diabetes mellitus patients. Int J Cancer. 2013;132:182–8.CrossRefPubMedGoogle Scholar
  6. 6.
    Lee JY, Jeon I, Lee JM, Yoon JM, Park SM. Diabetes mellitus as an independent risk factor for lung cancer: a meta-analysis of observational studies. Eur J Cancer. 2013;49:2411–23.CrossRefPubMedGoogle Scholar
  7. 7.
    Barone BB, Yeh HC, Snyder CF, Peairs KS, Stein KB, Derr RL,et al. Postoperative mortality in cancer patients with preexisting diabetes: systematic review and meta-analysis. Diabetes Care. 2010;33:931–9.CrossRefPubMedPubMedCentralGoogle Scholar
  8. 8.
    Jeong SS, Choi PJ, Yi JH, Yoon SS. Impact of lifestyle diseases on postoperative complications and survival in elderly patients with stage I non-small cell lung cancer. Korean J Thorac Cardiovasc Surg. 2017;50:86–93.CrossRefPubMedPubMedCentralGoogle Scholar
  9. 9.
    Hatlen P, Grønberg BH, Langhammer A, Carlsen SM, Amundsen T. Prolonged survival in patients with lung cancer with diabetes mellitus. J Thorac Oncol. 2011;6:1810–7.CrossRefPubMedGoogle Scholar
  10. 10.
    Imai H, Kaira K, Mori K, Ono A, Akamatsu H, Matsumoto S, et al. Prognostic significance of diabetes mellitus in locally advanced non-small cell lung cancer. BMC Cancer. 2015;15:989. Scholar
  11. 11.
    Kurishima K, Watanabe H, Ishikawa H, Satoh H, Hizawa N. Survival of patients with lung cancer and diabetes mellitus. Mol Clin Oncol. 2017;6:907–10.CrossRefPubMedPubMedCentralGoogle Scholar
  12. 12.
    Bartling B, Simm A, Sohst A, Silber RE, Hofmann HS. Effect of diabetes mellitus on the outcome of patients with resected non-small cell lung carcinoma. Gerontology. 2011;57:497–501.CrossRefPubMedGoogle Scholar
  13. 13.
    Zhu L, Cao H, Zhang T, Shen H, Dong W, Wang L, et al. The effect of diabetes mellitus on lung cancer prognosis: a PRISMA-compliant meta-analysis of cohort studies. Medicine (Baltimore). 2016;95:e3528. Scholar
  14. 14.
    Dhillon SS, Groman A, Meagher A, Demmy T, Warren GW, Yendamuri S. Metformin and not diabetes influences the survival of resected early stage NSCLC patients. J Cancer Sci Ther. 2014;6:217–22.PubMedPubMedCentralGoogle Scholar
  15. 15.
    International Expert Committee. International Expert Committee report on the role of the A1C assay in the diagnosis of diabetes. Diabetes Care. 2009; 32: 1327–34.CrossRefGoogle Scholar
  16. 16.
    World Health Organization. Histological typing of lung and pleural tumors. 3rd ed. Geneva: Springer; 1999.Google Scholar
  17. 17.
    Goldstraw P, Crowley J, Chansky K, Giroux DJ, Groome PA, Rami-Porta R, et al. The IASLC Lung Cancer Staging Project: proposals for the revision of the TNM stage groupings in the forthcoming (seventh) edition of the TNM classification of malignant tumours. J Thorac Oncol. 2007; 2:706–14.CrossRefPubMedGoogle Scholar
  18. 18.
    Luo J, Chen YJ, Chang LJ. Fasting blood glucose level and prognosis in non-small cell lung cancer (NSCLC) patients. Lung Cancer. 2012;76:242–7.CrossRefPubMedGoogle Scholar
  19. 19.
    Rao Kondapally Seshasai S, Kaptoge S, Thompson A, Di Angelantonio E, Gao P, Sarwar N, et al. Diabetes mellitus, fasting glucose, and risk of cause-specific death. N Engl J Med. 2011;364:829–41.CrossRefPubMedPubMedCentralGoogle Scholar
  20. 20.
    Peters G, Gongoll S, Langner C, Mengel M, Piso P, Klempnauer J, et al. IGF-1R, IGF-1 and IGF-2 expression as potential prognostic and predictive markers in colorectal-cancer. Virchows Arch. 2003;443:139–45.CrossRefPubMedGoogle Scholar
  21. 21.
    Ma J, Li H, Giovannucci E, Mucci L, Qiu W, Nguyen PL, et al. Prediagnostic body-mass index, plasma C-peptide concentration, and prostate cancer-specific mortality in men with prostate cancer: a long-term survival analysis. Lancet Oncol. 2008;9:1039–47.CrossRefPubMedPubMedCentralGoogle Scholar
  22. 22.
    AGryko M, Kiśluk J, Cepowicz D, Zińczuk J, Kamocki Z, Guzińska-Ustymowicz K, et al. Expression of insulin-like growth factor receptor type 1 correlate with lymphatic metastases in human gastric cancer. Pol J Pathol. 2014;65:135–40.Google Scholar
  23. 23.
    Zhang M, Li X, Zhang X, Yang Y, Feng Z, Liu X. Association of serum hemoglobin A1c, C-peptide and insulin-like growth factor-1 levels with the occurrence and development of lung cancer. Mol Clin Oncol. 2014;2:506–8.CrossRefPubMedPubMedCentralGoogle Scholar
  24. 24.
    Hsu CN, Chang CH, Lin YS, Lin JW, Caffrey JL. Association of serum C-peptide concentrations with cancer mortality risk in pre-diabetes or undiagnosed diabetes. PLoS One. 2013;8(2):e55625. Scholar
  25. 25.
    Kim JS, Kim ES, Liu D, Lee JJ, Solis L, Behrens C, et al. Prognostic impact of insulin receptor expression on survival of patients with nonsmall cell lung cancer. Cancer. 2012;118:2454–65.CrossRefPubMedGoogle Scholar
  26. 26.
    Kim JS, Kim ES, Liu D, Lee JJ, Solis L, Behrens C, et al. Prognostic implications of tumoral expression of insulin like growth factors 1 and 2 in patients with non-small-cell lung cancer. Clin Lung Cancer. 2014;15:213–21.CrossRefPubMedPubMedCentralGoogle Scholar
  27. 27.
    Zhao S, Qiu Z, He J, Li L, Li W. Insulin-like growth factor receptor 1 (IGF1R) expression and survival in non-small cell lung cancer patients: a meta-analysis. Int J Clin Exp Pathol. 2014;7:6694–704.PubMedPubMedCentralGoogle Scholar
  28. 28.
    Gately K, Forde L, Cuffe S, Cummins R, Kay EW, Feuerhake F, et al. High coexpression of both EGFR and IGF1R correlates with poor patient prognosis in resected non-small-cell lung cancer. Clin Lung Cancer. 2014;15:58–66.CrossRefPubMedGoogle Scholar
  29. 29.
    Yeo CD, Park KH, Park CK, Lee SH, Kim SJ, Yoon HK, et al. Expression of insulin-like growth factor 1 receptor (IGF-1R) predicts poor responses to epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors in non-small cell lung cancer patients harboring activating EGFR mutations. Lung Cancer. 2015;87:311–7.CrossRefPubMedGoogle Scholar

Copyright information

© Springer Japan KK, part of Springer Nature 2017

Authors and Affiliations

  • Makoto Motoishi
    • 1
  • Satoru Sawai
    • 2
  • Tetsuo Hori
    • 1
  • Naoki Yamashita
    • 1
  1. 1.Department of Thoracic SurgeryMitsubishikyoto HospitalKyotoJapan
  2. 2.Department of Thoracic SurgeryNational Hospital Organization Kyoto Medical CenterKyotoJapan

Personalised recommendations